Table 3.
drug/alcohol use and access to methadone treatment among the participants in the cohort sample between RDS and week 52.
| RDS N = 250 N (%) |
W12 N = 229 N (%) |
W24 N = 214 N (%) |
W52 N = 194 N (%) |
|
|---|---|---|---|---|
| Intravenous heroin use N (%) | ||||
| - No | 0 (0.0%) | 5 (2.2%) | 39 (18.2%) | 54 (27.8%) |
| - Yes, less than once or once a day | 15 (6.0%) | 163 (71.2%) | 108 (50.5%) | 53 (27.3%) |
| - Yes, more than once a day | 235 (94.0%) | 61 (26.6%) | 67 (31.3%) | 87 (44.8%) |
| Non-intravenous heroin use N (%) | 6 (2.4%) | 9 (3.9%) | 14 (6.5%) | 16 (8.2%) |
| Non-intravenous methamphetamine use N (%) | 58 (23.2%) | 30 (13.1%) | 54 (25.2%) | 78 (40.2%) |
| Alcohol use (Audit-c) N (%) | ||||
| - Hazardous drinkinga | 54 (21.7%) | 57 (29.4%) | ||
| - Binge drinkingb | 14 (5.6%) | 21 (10.8%) | ||
| Participants who had initiated methadone treatment before or at the visit | 11 (4.4%) | 79 (34.5%) | 109 (51.2%) | 139 (71.6%) |
| - Participants with heroin urine test positive | 11 (100%) | 78 (72.2%) | 92 (66.2%) |
a
Hazardous drinking: Audit-c score ≥3 in women and ≥4 in men, 1 missing data.
b
Binge drinking: 6 or more drinks on one occasion daily or almost daily, weekly or monthly, 1 missing data.